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Sphingosine kinase 1 (SphK1) is a lipid kinase that
catalyzes the conversion of sphingosine to sphingo-
sine-1-phosphate (S1P), which has been shown to
play a role in lymphocyte trafficking, angiogenesis,
and response to apoptotic stimuli. As a central
enzyme in modulating the S1P levels in cells,
SphK1 emerges as an important regulator for diverse
cellular functions and a potential target for drug
discovery. Here, we present the crystal structures
of human SphK1 in the apo form and in complexes
with a substrate sphingosine-like lipid, ADP, and an
inhibitor at 2.0–2.3 A˚ resolution. The SphK1 struc-
tures reveal a two-domain architecture in which its
catalytic site is located in the cleft between the two
domains and a hydrophobic lipid-binding pocket
is buried in the C-terminal domain. Comparative
analysis of these structures with mutagenesis and
kinetic studies provides insight into how SphK1
recognizes the lipid substrate and catalyzes ATP-
dependent phosphorylation.
INTRODUCTION
Sphingolipids are important bioactive lipid signalingmolecules in
the regulation of many cellular processes (Hannun and Obeid,
2008; Ponnusamy et al., 2010). Among them, sphingosine-1-
phosphate (S1P) has emerged as a crucial player in various
physiological processes, including cancer and inflammation
(Beaven, 2007; Brinkmann et al., 2010; Maceyka et al., 2012;
Pyne and Pyne, 2010; Pyne et al., 2012a). A broad spectrum of
roles has been established for this pleiotropic phospholipid.
S1P has been shown to play a vital role in diverse biological pro-
cesses, including lymphocyte trafficking, cell growth, apoptosis,
mitogenesis, chemosensitization, and angiogenesis (Chi, 2011;
Cuvillier et al., 1996; English et al., 1999; Hannun and Obeid,
2008; Kihara et al., 2007; Olivera and Spiegel, 1993; Rosen
and Goetzl, 2005; Spiegel and Milstien, 2011; Strub et al., 2010).
S1P is generated by the action of sphingosine kinases (SphKs),
which catalyze the ATP-dependent phosphorylation of sphingo-
sine on its primary hydroxyl group. SphKs constitute a distinct
class of lipid kinase family that is evolutionarily highly conserved798 Structure 21, 798–809, May 7, 2013 ª2013 Elsevier Ltd All rights(Kohama et al., 1998; Taha et al., 2006). They do not share
sequence homology with other lipid kinases, such as phosphati-
dylinositol-3 kinase (PI3K). Five conserved domains (C1–C5)
have been identified within SphKs, with C1–C3 and C5 sharing
homology with diacylglycerol kinase (DGK) and ceramide kinase,
andC4being unique for SphKs. Twomammalian isoforms known
as SphK1 and SphK2 have been characterized (Kohama et al.,
1998; Liu et al., 2000;Melendez et al., 2000;Nava et al., 2000;Oli-
vera et al., 1998; Pitson et al., 2000). Although SphK1 and SphK2
catalyze the same biochemical reactions, they originate from
different genes and present different substrate specificities, tis-
sue distributions, and subcellular localization patterns (Liu
et al., 2003;Maceyka et al., 2005; Taha et al., 2006). Interestingly,
knockout studies show that mice lacking either SphK1 or SphK2
were viable and fertile and had no obvious abnormality (Allende
et al., 2004; Mizugishi et al., 2005). However, deletion of both
these genes in mice proved to be lethal to the embryo, which ex-
hibited severe defects in neurogenesis and angiogenesis (Mizu-
gishi et al., 2005). These studies suggest that SphK1 and
SphK2 have at least some functional redundancy.
SphK1 has intrinsic catalytic activity, but it can be further acti-
vated by a range of membrane receptors and signaling mole-
cules. These include G protein coupled receptors (GPCRs),
growth factors, proinflammatory cytokines, and hormones,
which stimulate SphK1, leading to a rapid increase in S1P levels
that in-turn modulates a number of signaling pathways (Hannun
and Obeid, 2008; Pan et al., 2011; Spiegel and Milstien, 2003). In
addition to agonist activation, localization of SphK1 appears to
be another factor critical to its production of S1P that mediates
the downstream signaling function (Wattenberg et al., 2006).
Phosphorylation at Ser225 of SphK1 by extracellular-signal-
regulated kinase (ERK1/2) not only increases SphK1 activity,
but also promotes translocation of SphK1 from the cytoplasm
to the plasma membrane (Pitson et al., 2003, 2005). Thus, the
biology behind SphK1 action is multifaceted.
Elevated expression of SphK1 is observed in a wide range of
cancers, including solid tumors of the breast, colon, lung, ovary,
stomach, uterus, kidney, and rectum, as well as in leukemia
(Alshaker et al., 2013; Heffernan-Stroud and Obeid, 2013). Upre-
gulation of SphK1 has been associated with tumor angiogenesis
or lymphangiogenesis and with radiation or chemotherapy resis-
tance and sensitivity (Gault and Obeid, 2011; Pitman and Pitson,
2010; Pyne et al., 2012b; Shida et al., 2008). Hence, SphK1
presents a promising novel molecular target for therapeutic
intervention in cancer and inflammatory diseases (Antoonreserved
Table 1. X-ray Data Collection and Refinement Statistics
Data Collection Native Phasing SeMet-SphK1 (MAD)
Data set ‘‘apo’’ SKI-II SKI-II+ADP Peak Edge High Remote Low Remote
Space group C2221 P212121 P212121 C2221
Cell Dimensions
a (A˚) 101.8 102.2 102.2 101.96 101.7 101.7 101.7
b (A˚) 226.2 106.6 106.6 229.4 228.2 227.8 227.7
c (A˚) 106.5 226.1 226.0 107.1 106.8 106.7 106.7
Wavelength (A˚) 1.000 1.0 1.0 0.9792 0.9793 0.9641 1.000








Completeness (%) 99.7 (97.9) 91.9 (85.7) 98.6 (97.1) 98.6 (88.2) 100 (100) 100 (100) 99.7 (98.4)
Average I/s (I) 13.2 (2.5) 12.2 (3.1) 13.5 (2.9) 34.2 (3.0) 56 (12) 41 (7.6) 25.3 (3.8)








Redundancy 3.5 (3.5) 3.4 (3.4) 3.6 (3.5) 13.2 (7.4) 14.6 (14.7) 9.8 (9.8) 4.1 (4.0)
Rmerge (%)
a 6.2 (48.8) 5.7 (38.1) 6.5 (36.8) 9.9 6.6 6.5 5.2
Refinement
Resolution range (A˚) 50–2.0 (2.11–2.0) 50–2.3 (2.42–2.3) 50–2.3 (2.42–2.3)
Number of Atoms
Protein 8,159 16,052 16,216
Solvent 382 292 358
Ligands 108 128 209
Average B-Factor (A˚2 )
Protein 38.7 43.9 38.8
Ligand 53.5 51.2 43.0
Solvent 41.5 38.0 35.7
R factorb 21.6 22.9 20.6
Rfree
c 26.4 28.5 26.9
rmsd bond lengths (A˚) 0.008 0.010 0.020
rmsd bond angles () 1.35 1.46 2.04
Values in parentheses refer to statistics in the highest-resolution shell. rmsd, root-mean-square deviation.
aRmerge = SjIobs  <I> j/SIobs.
bR factor = SjFobs  Fcalcj/SFobs, where Fobs and Fcalc are the observed and calculated structure-factor amplitudes, respectively.
cRfree was computed using 5% of the data assigned randomly.
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2008). Whereas the importance of SphK1 activity is well
established in several human pathologies, understanding the
molecular basis of SphK1 activation has been hampered by
the lack of three-dimensional crystal structure data for any
of the SphKs. Here, we present a crystal structure of human
SphK1 at 2.0 A˚ resolution without any added ligands. Moreover,
we have solved the SphK1 structures in the presence of an inhib-
itor and an inhibitor plus ADP, at 2.3 A˚ resolution in both cases.
RESULTS
Structure Determination
Since the full-length recombinant human SphK1 protein failed
to produce crystals, we generated a panel of protein con-
structs with a combination of N-terminal and C-terminal trunca-
tions to search for a soluble and crystallizable protein. The final
SphK1 protein used for crystallization contains residues 9–364
of the full-length 384 amino acids and is pure and catalyticallyStructure 21active (Figure S1 available online). The protein purified from the
baculovirus expression system has been crystallized both in
the apo form and in the presence of various combinations of
ATP and its analogs, substrate/product as well as inhibitors.
The crystal structure of apo SphK1 was determined first by the
multiwavelength anomalous dispersion (MAD) method using
crystals grown from selenomethionyl-enriched protein and
refined at 2.0 A˚ resolution in the space group C2221. There are
three molecules in the asymmetric unit, which are highly similar.
The final electron density maps are of high quality throughout the
protein (residues 9–364) for onemolecule, and of good quality for
the other two protein molecules, which have a few disordered
loop regions, including residues 186–187, 219–231, and 333–
335. The cocrystal structures of SphK1 in complex with an
SphK inhibitor, SKI-II (French et al., 2003, 2006), and in complex
with ADP and SKI-II were solved by molecular replacement, in
both cases at 2.3 A˚ resolution in the space group P212121, with
six molecules in the asymmetric unit. Crystallographic statistics
are shown in Table 1., 798–809, May 7, 2013 ª2013 Elsevier Ltd All rights reserved 799
Figure 1. Overall Structure of SphK1
(A) Cartoon representations of the SphK1 structure in two orientations. The ribbon diagram is colored in a spectrum color that starts with blue for the N terminus
and ends in red for the C terminus.
(B) Secondary structure of human SphK1 and sequence alignment with human SphK2. Double slashes indicate a large insertion in the sequence of SphK2.
See also Figure S1.
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Figure 2. Structural Comparison of SphK1 with DGK
and NAD Kinase
(A) Superposition of human SphK1 (cyan) and DGK from
Staphylococcus aureus (DgkB) (gray, Protein data Bank
[PDB] code 2QVL).
(B) Superposition of human SphK1 and an NAD kinase from
Archaeoglobus fulgidus (magenta, PDB code 1ZOZ).
Structure
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The overall structure of SphK1 (residues 9–364) adopts a two-
domain architecture that comprises nine a helices, 17 b strands,
and a 310-helix (Figure 1). The N-terminal domain (NTD) (residues
9–150 and 357–364, containing the C1–C3 domains) adopts an
a/b fold and comprises six a helices (a1-a6) and six b strands
(b1–b5 and b17), resembling the dinucleotide binding motif of a
Rossmann fold of a three-layer a/b/a sandwich. The core of
the NTD is a twisted parallel four-stranded b sheet (strand order,
b2, b1, b3, b4), which is extended by a substructure of antipar-
allel strands b17 and b5, with strand b17 running in part parallel
to strand b4. The central b sheet is flanked by three a helices on
each side: a2, a3, and a4 on one side and a1, a5, and a6 on the
other side. Note that the C-terminal strand b17 forms the 6th b
strand of the NTD, a feature of the swapping of secondary-struc-Figure 3. Lipid Substrate Binding in SphK1
(A) Binding mode of sphingosine in the CTD of SphK1. The bound sphingosine lipid is shown in stick
purple for oxygen, nitrogen, and carbon atoms, respectively. SphK1 is colored as in Figure 1. A 2Fo-
mesh and contoured at 1s.
(B) Detailed lipid-protein interactions between sphingosine and SphK1. Side chains of SphK1 w
representation. Hydrogen-bond interactions are denoted by magenta dashed lines. A water molec
Structure 21, 798–809, Mayture elements between the two domains. The
C-terminal domain (CTD) (residues 151–356, con-
taining the C4 and C5 domains) comprises 11 b
strands and four helices. The 11 b strands are
arranged into a two-layer antiparallel b sandwich,
with the ‘‘back’’ sheet comprising the antiparallel
b strands b7, b6, b16, b13, and b9 and the ‘‘front’’
sheet containing b15, b14, b8, b10, b11, and b12.
Three a helices, a7–a9, and a 310 helix following
helix a9, pack onto the front sheet of the sand-wich, whereas a long coiled loop (loop b9–b10, residues 214–
256) covers the back sheet.
Protein sequence motif analysis and structure classification
suggested that SphKs belong to the phosphofructokinase
(PFK)-like superfamily (Cheek et al., 2005; Labesse et al.,
2002), sharing the same protein fold with NAD kinases, DGKs,
and ceramide kinases, as well as PFKs that are more distantly
related to it. Indeed, the SphK1 structure bears no similarity to
protein kinases or other lipid kinases, such as PI3K. The overall
fold of SphK1 manifests a two-domain architecture similar to
those of NAD kinases (Garavaglia et al., 2004; Liu et al., 2005;
Mori et al., 2005; Poncet-Montange et al., 2007) and DGKs
(Bakali et al., 2007; Miller et al., 2008; Nichols et al., 2007),
even though SphK1 shares with them a very low overall
sequence identity of 10%–20% over 250 residues (Figure 2).representation with an atomic color scheme of red, blue, and
Fc electron density map for the lipid molecule is shown in teal
ithin a distance of 5 A˚ from the lipid are shown in thin stick
ule is shown as a red sphere.
7, 2013 ª2013 Elsevier Ltd All rights reserved 801
Figure 4. Lipid-Binding Pocket in holo and
apo SphK1
(A) The lipid-binding pocket with bound sphingo-
sine. The protein is shown in electrostatic molec-
ular surface representation. The lipid is shown in
stick representation with its van der Waals surface
shown in dots.
(B) The lipid-binding pocket in the lipid-free SphK1
molecule with overlaid sphingosine molecule
shown in molecular surface dots.
(C) Superposition of lipid-bound SphK1 (cyan)
and lipid-free SphK1 (pink). The lipid gate in apo
SphK1 is colored in red. The sphingosine molecule
is shown in molecular surface representation in
purple.
(D) A plot of the rmsd of Ca atoms versus the
residue number between the apo and lipid-bound
SphK1 molecules. The superposition was carried
out using the sequence of residues 9–360.
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Molecular Basis of Sphingosine Kinase 1 RegulationHowever, SphK1 displays substantial structural differences from
either NAD kinases or DGKs, especially in the CTD. Most notable
of these is that SphK1 possesses a distinct helical arrangement
folded on the front sheet of the b sandwich and a coiled loop on
the back sheet in the CTD.
Lipid Binding to the CTD
Upon completion of the model building of the SphK1 structure,
we noticed an extra J-shaped piece of electron density in the
CTD for two of the three molecules in the asymmetric unit,
between the four helices and the front sheet of the b sandwich
(Figure 3A), while there was little extra density for the 3rd mole-
cule. This J-shaped densitymatcheswell with a 14- to 18-carbon
alkyl chain. Two reasonable candidates are (1) a molecule of
detergent Tween 20 that was used in protein purification and
crystallization, and (2) endogenous sphingosine substrate or
one of its derivatives, because no exogenous sphingosine was
added in our experiments. The long aliphatic chains of both
Tween 20 and sphingosine fit the J-shaped density equally
well. However, the sphingosine head group corresponds to the
size of the density relatively well, whereas the polar head group
of Tween 20 is much too big for the density. We made various
attempts to pinpoint the identity of this molecule, because the
intracellular C14 or C16 sphingoid bases present at low concen-
tration in insect cells might remain associated with this insect-
cell-expressed protein (Fyrst et al., 2004). Mass-spectrometry
analysis was inconclusive in identifying whether C14 or C16802 Structure 21, 798–809, May 7, 2013 ª2013 Elsevier Ltd All rights reserved‘‘sphingosine’’ (sphingoid bases) or
sphingosine (C18) was present in the pro-
tein used for crystallization. Because all
these sphingoid bases share the same
amino alcohol head group, which is the
key group involved in catalysis, the differ-
ence in the alkyl chain length in C14–C18
‘‘sphingosine’’ is less significant. Howev-
er, sphingosine (C18) provided the best
fit and crystallographic refinement, into
this J-shaped density seen for two mole-
cules (one shown in Figure 3A).The binding of ‘‘sphingosine’’ to SphK1 is mediated by both
the anchoring of the hydrophilic head group to the protein sur-
face and the accommodation of the hydrophobic alkyl chain in
the interior of the protein. The 2-amino-1,3-diol moiety of the
sphingosine head group is situated at the cleft between the
two domains, making hydrogen-bond interactions with Asp81
of loop b3-a3 (residues S79–G82) through the 1-hydroxyl and
with Asp178 of helix a7 through the 3-hydroxyl, which also forms
a water-mediated hydrogen bond with Ser168 of strand b8 (Fig-
ure 3B). The long acyl chain is buried in a hydrophobic J-shaped
tunnel, lined by the side chains of mostly nonpolar residues from
strands b10–b12 of the front sheet of the b sandwich, loop b10-
b11, helices a7–a9, and the 310 helix. These residues include
Phe173, Ile174, and Val177 of helix a7; Phe192 and Thr196 of
helix a8; Leu299, Leu302, Phe303, and Met306 of helix a9;
His311 of helix 310; Leu319 of strand b12; Phe288 and Val290
of strand b11; Leu259 and Leu261 of strand b10, Ala170 of
strand b8, and Leu268, Met272, and Ala274 of loop b10-b11.
The lipid-binding cavity manifested by this ‘‘sphingosine’’-
bound SphK1 molecule is almost completely buried, leaving
only a small entrance of 8.5 A˚ diameter around the polar
head group in the cleft between the NTD and CTD (Figure 4A).
This led us to question whether the lipid molecule enters the
cavity by a tunneling mechanism, by introducing the hydropho-
bic tail through the entrance and pushing through the surround-
ing hydrophobic residues, resulting in the observed induced fit in
the pocket. Examination of the apo molecule, which lacks extra
Figure 5. Inhibitor SKI-II Binding in SphK1
(A) Chemical structure of SKI-II. This inhibitor has a reported IC50 around 0.5 mM for GST-human SphK1 (French et al., 2003).
(B) SKI-II binding in the lipid-binding pocket of SphK1with overlaid sphingosine lipid. The protein is shown in light greenmolecular surface representation. SKI-II is
shown in stick representation colored with an atomic color scheme of red, blue, yellow, green, and magenta for oxygen, nitrogen, sulfur, chlorine, and carbon
atoms, respectively. Sphingosine is denoted as in Figure 3.
(C) Detailed ligand-protein interactions between SKI-II and SphK1. The lipid-binding pocket is shown as a ribbon diagram. The important interfacial side chains
are shown in stick representation in the atomic color scheme of light green for carbon atom.
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a comparable entrance around the head group in comparison
with the holo enzyme. In addition, there is a side opening with
a dimension of 10 A˚ along the lipid molecule (Figure 4B).
The solvent-accessible volume of the lipid-binding pocket is
measured to be about 400 A˚3 and 700 A˚3 for the holo and apo
enzymes, respectively, indicating that the lipid-binding cavity
preexists in the free form and does not result as a consequence
of the lipid binding.
Superposition of the apo and lipid-bound SphK1 structures re-
veals essentially no differences in the majority of the protein but
an evidentmovement in the region of helix a7 to helix a8 in the C4
domain (Figure 4C). The two molecules can be superimposed
with an rmsd of 1.14 A˚ for 336 Ca atoms (almost all residues
except a very few residues at the N terminus), and an rmsd of
0.78 A˚ for 309 Ca atoms, by excluding the residues from a7 to
a8, which showed the most deviation (Figure 4D). Both helices
a7 and a8 move outward and the loop a7-a8 (residues
Glu182–Glu189) remodels completely, leading to the additional
side opening in the apo structure (Figure 4B). The crystallo-
graphic B-factor distribution substantiates a higher conforma-
tional mobility for the segment of helix a7-a8 in this area. Thus,
our structural analysis suggests that this segment of a7-a8 in
SphKs might act like a lipid gate that controls the in-and-out of
lipid substrate and product.
Binding of Inhibitor SKI-II in the Lipid-Binding Pocket
Whereas the effort to cocrystallize various substrate/product
analogs suchasN,N-dimethyl sphingosine andS1P failed to yield
ligand-bound structures, using a previously reported inhibitor,
SKI-II, which inhibits both SphK1 and SphK2 (French et al.,
2003, 2006) (Figure 5A), for cocrystallization with SphK1 was
successful. The electron density for the inhibitor was well
resolved inall sixmolecules in theasymmetric unit of thecocrystal
structure solved in space group P212121 at a resolution of 2.3 A˚.Structure 21SKI-II occupies the distal end of the enclosed lipid pocket
where the alkyl chain of ‘‘sphingosine’’ binds (Figure 5B), with
the chlorophenyl ring sitting at the end of the pocket and the
phenol moiety pointing toward the opening in the cleft between
the NTD and the CTD. The hydroxyl moiety of the phenol is mak-
ing a hydrogen bond to Asp178 of helix a7, leading to a closed
conformation for the lipid gate. The amino group is also within
hydrogen-bond distance of the hydroxyl of Thr196 of helix a8
(Figure 5C). At the other end, the Cl atom makes close contact
with the aromatic ring of Phe288. The rest of the molecule forms
numerous van der Waals interactions with a similar set of
nonpolar residues that recognize the hydrophobic tail of the lipid
substrate. Here, the structure clearly indicates that SKI-II is a
lipid substrate competitive inhibitor, rather than being an ATP-
site inhibitor like most inhibitors of protein kinases.
Nucleotide Binding in the Cleft between the NTD and
the CTD
Our efforts to cocrystallize various nucleotides, including ATP,
ADP, and AMP, in combination with substrate/product analogs
and inhibitors led us to a ternary-complex structure of SphK1
with ADP and SKI-II at a resolution of 2.3 A˚. All six independent
SphK1 molecules in the P212121 asymmetric unit show well-
defined electron density for inhibitor SKI-II, and the inhibitor
binding mode is virtually identical to that in the binary complex
of SphK1 with SKI-II. On the other hand, only two of the six
SphK1 molecules revealed continuous density for the nucleo-
tide. Hence, in addition to the six molecules of inhibitor SKI-II,
we modeled in ADP and a Mg2+ ion for two of six SphK1 mole-
cules in the final model.
The nucleotide binding site lies in an extended cleft between
the NTD and the CTD (Figure 6A). ADPmanifests extensive inter-
actions with the protein, as shown in Figure 6B. The adenine ring
is sandwiched between loop b1-a1 (residues 22–29, the C1
domain) and loop b2-a2 (residues 54–58), making p stacking, 798–809, May 7, 2013 ª2013 Elsevier Ltd All rights reserved 803
Figure 6. ADP Binding in SphK1
(A) Ribbon diagram of SphK1 in complex with ADP and SKI-II. The protein is colored wheat. ADP is shown in stick representation with the atomic color scheme of
silver and green for carbon and phosphorus atoms. SKI-II is colored as in Figure 6. A Mg2+ ion is denoted by a brown sphere.
(B) Detailed interactions between ADP and SphK1. The important interfacial residues of SphK1 are shown in stick representation, with carbon atoms colored
yellow. Hydrogen-bond interactions are denoted by magenta dashed lines.
(C) Superposition of the SphK1/ADP/SKI-II and the DgkB/ADP complex structures. SphK1 and DgkB (PDB code 2QV7) are colored wheat and dark gray,
respectively.
(D) Superposition of the SphK1/ADP/SKI-II and the NAD-kinase/ADP/POP complex structures. The NAD-kinase structure (PDB code 1ZOS) is colored deep
purple.
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A B Figure 7. Proposed SphK1 Catalytic
Machinery
(A) Superposition of the SphK1/‘‘sphingosine’’ and
SphK1/ADP/SKI-II complex structures with a
modeled ATP molecule. The color schemes are as
in Figure 3 and Figure 5 for the SphK1/sphingosine
and SphK1/ADP/SKI-II structures, respectively.
The ADP and SKI-II molecules have been omitted
from the figure for clarity. The modeled ATP
molecule is colored in an atomic color scheme
similar to that of ADP in Figure 6, except that the
carbon atoms are yellow.
(B) Kinetics of human SphK1 proteins. Michaelis-
Menten plots of ATP conversion to ADP are shown
for wt SphK1, the D81N and D81A mutants.
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side chain of Asn22. The ring also makes two hydrogen-bond
interactions with Thr54 of loop b2-a2—theN6 amino group binds
to the backbone carbonyl of Thr54 and the N7 atom to the side-
chain hydroxyl of Thr54. The C20 and C30 ribose hydroxyls are
hydrogen bonded to the side chains of Glu86 of helix a3 (the C2
domain) and Glu343 of loop b14-b15 (residues 340–343, the C5
domain), respectively. The a-phosphate, sitting at the N-terminal
end of helix a3, is in close contact with loop a3-b3 (residues 79–
82, the C2 domain). One oxygen atom of the a-phosphate is
hydrogen bonded to the hydroxyl of Ser79 and the backbone
amide of Gly80. The other oxygen atom of the a-phosphate is
coordinatedwith aMg2+ ion that also interactswith the backbone
carbonyl of Asp341 and side chain of Glu343 of loop b14-b15.
The b-phosphate forms several hydrogen bondswith the protein,
bridging both the NTD and the CTD, including the side chains of
Arg185 of loop a7-a8 (residues 184–189, the C4 domain) and
Arg191 of helix a8 and backbone amides of Ser112 and
Gly113, as well as the side-chain hydroxyl of Ser112 of loop b4-
a5 (residues 109–115, theC3domain). In summary, our structural
elucidation of the ADP binding demonstrates the presence of an
extensive nucleotide binding site in SphK1, with contributions
from all five conserved domains.
We compared the nucleotide binding in SphK1 with those of
the DGKs and NAD kinases in the PFK-like superfamily. ADP
binding in SphK1 bears a close resemblance to that in DgkB, a
prokaryotic DGK isoform B (Figure 6C), except that the Mg2+
ion identified there binds at a distal site of 24 A˚ from the
b-phosphate of ADP in DgkB (Miller et al., 2008). However, the
complex structure of an NAD kinase from Archaeoglobus fulgidu
with ATP presents a rather different ATP binding mode (Fig-
ure 6D), in which the AMP portion of ATP occupies the same
site as the nicotinamide ribose portion of substrate NAD/NADP
in the NAD/NADP bound structures (Liu et al., 2005). Instead,
an additional pyrophosphate moiety binds at the same site as
the a- and b-phosphate groups of ADP in SphK1. A Mg2+ ion
in the NAD-kinase complex structure binds at a similar location
to that seen in SphK1 and is coordinated to both the g-phos-
phate group of ATP and the pyrophosphate moiety.Structure 21, 798–809, May 7, 2013Model of Catalytic Machinery
By superimposing the ‘‘sphingosine’’-
bound and ADP/inhibitor-SKI-II-bound
SphK1 structures, we constructed amodel of SphK1 bound with ADP and the lipid ‘‘sphingosine’’
that serves as a plausible depiction of the catalytic machinery
of SphK1. The model suggests that the polar head group of
sphingosine is in close proximity (6 A˚) to the b-phosphate
group.We thenmodeled in the g-phosphate for an ATPmolecule
based on the bound ADP molecule. As shown in Figure 7A, the
1-hydroxyl of sphingosine is about 2.5 A˚ from the oxygen atom
of the modeled g-phosphate and is in a suitable position for
nucleophilic attack on the g-phosphate for direct phosphoryl
transfer. On the other side of the 1-hydroxyl lies the side chain
of Asp81 from the sequence S79GDG82 of loop b3-a3, which is
in a direct hydrogen-bonding distance to the O1 atom. Note
that Asp81 is conserved in SphK1 and SphK2. Here, Asp81
appears to act as a general base catalyst that deprotonates
and increases the nucleophilicity of the 1-hydroxyl of sphingo-
sine for the phosphoryl transfer.
To corroborate the role of Asp81 in catalysis, we generated
both alanine and asparagine substitution mutants for Asp81
and performed kinetic analysis. The Km and Kcat values
for ATP are 20.0 mM and 2.56 min1, respectively, when
D-erythro-sphingosine is used as the substrate for wild-type
(wt) SphK1 (Figure 7B). Although the D81N mutant displays a
similar Km value of 25.5 mM but has a greatly reduced Kcat of
0.04 min1 compared with wt SphK1, D81A shows essentially
no activity for phosphoryl transfer and ADP formation. These
data indicate that Asp81 plays a critical role in the phosphoryl
transfer step, but not in the binding of ATP, which is completely
consistent with our structural observations. Taking all these data
together, we have established Asp81 as a catalytically critical
residue for SphK1 kinase function.
DISCUSSION
Our SphK1 structures of apo, ADP-bound, and ‘‘lipid’’-molecule-
bound forms reveal the potential lipid substrate recognition and
catalytic machinery for the lipid kinase SphK family. The two-
domain architecture resembles that of DGK and NAD kinases
in the PFK-like superfamily, but not those of other lipids or pro-
tein kinases. The lipid molecule is shown to bind deeply in theª2013 Elsevier Ltd All rights reserved 805
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lipid-binding cavities compared with DGKs and NAD kinases,
thereby granting the substrate specificity for lipid sphingosine.
A comparative analysis of the apo and holo SphK1 structures
suggests that the segment of helices a7-a8 in the C4 domain
might act as a lipid gate that could open and close to let the lipid
substrate and product in and out of the preexisting lipid-binding
cavity in the CTD, as an alternative to a possible tunneling mech-
anism. In the lipid-bound, gate-closed form, Asp178 of helix a7
stabilizes the lipid binding by making a hydrogen bond with the
4-hydroxyl of ‘‘sphingosine.’’ These data are in good agreement
with an earlier biochemical report that the corresponding Asp177
in mouse SphK1 was involved in recognition of sphingosine (Yo-
kota et al., 2004).
Together with the lipid binding, the elucidation of the ADP
binding site provides a clear illustration for the catalytic site in
SphK1, which involves all five conserved domains. The 1-hy-
droxyl of sphingosine is in close proximity to the g-phosphate
of the modeled ATP molecule, ready for an in-line phosphoryl
transfer. A motif of S79GDGX17-21K
103 identified as the nucleo-
tide-binding site in SphKs was proposed to be analogous to
the glycine-rich loop that anchors and positions the nucleotide
in the catalytic site of most protein kinases (Pitson et al., 2002).
Here, our structures suggest that the S79GDG82 motif acts as a
double agent, binding not only to the nucleotide but also to
the lipid substrates, with Asp81 serving as a catalytic base for
ATP catalysis. Both Ser79 and Gly82 are engaged in direct
hydrogen-bond interactions with the nucleotide, which substan-
tiates the biochemical observation of Gly82 being involved in
ATP binding (Pitson et al., 2002). In addition to the residues in
the S79GDG82 motif, a number of other residues were also
studied with regard to their roles in SphK1 regulation (Pitson
et al., 2001, 2002; Yokota et al., 2004). Most of these muta-
genesis results can be rationalized by the structural data. For
example, G113A was reported to increase SphK1 catalytic effi-
ciency (Pitson et al., 2001). Structurally, Gly113 is located in
close proximity to ADP but forms no direct interactions. Mutation
of Gly to Ala at this positionmight result in direct interactions with
the nucleotide. However, residue Lys103, which was speculated
(Pitson et al., 2002) to be like the catalytic lysine in protein
kinases, is not positioned in the active site at all. It is located at
the opposite side of the NTD in relation to the active site, with
a distance of about 18 A˚ from catalytic Asp81 (Ca-Ca).
Although the nucleotide-binding mode of SphK1 bears a close
resemblance to that of DgkB (Miller et al., 2008), the complex
structure of SphK1 with ADP presents a catalytically competent
conformation of the enzyme, in contrast to that of DgkB com-
plexed with ADP. The catalytically incompetent conformation
observed for DgkB was proposed, based on modeling, to be a
mid-range conformation between the predicted ‘‘open’’ (inac-
tive) and ‘‘closed’’ (active) forms (Miller et al., 2008). By compar-
ison, our SphK1 structures in the absence and presence of
bound nucleotide showed no change in the overall protein fold,
nor were there significant changes seen for the catalytic base
Asp81. Only some very local loop movements near the b-phos-
phate moiety are observed in the ADP-bound form, including
loop b1-a1of residues 24–27 and loop a7-a8 of residues 184–
189. Because there are numerous structural differences
between SphK1 and DgkB at both the catalytic and substrate-806 Structure 21, 798–809, May 7, 2013 ª2013 Elsevier Ltd All rightsbinding sites, in particular the distinct difference between
catalytic base residue Asp81 in SphK1 and Glu273 in DgkB (cor-
responding to residue Glu343 in SphK1), it remains unclear
whether SphK1 would undergo a hinge-like motion like that pre-
dicted for DgkB.
S1P is now well recognized as a crucial regulator of diverse
physiological processes, including cancer and inflammation.
As SphK1 is one of the key enzymes regulating the S1P level in
cells, understanding the molecular function of SphK1 is impera-
tive. Through the structural elucidation of SphK1 in various
forms, we demonstrate the overall fold of the enzyme and reveal
the catalytic site and potential lipid-binding pocket. Thus, our
structural study provides important molecular insights into the
SphK1 function and paves the road for more advanced studies
to fully comprehend the intricate SphK1 biology. Furthermore,
the inhibitor cocrystal structure determination has also laid a
solid foundation for development of small-molecule inhibitors
that target SphK1 activity.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The construct of truncated human SphK1 (residues 9–364 of the full 384 amino
acids) was PCR-cloned into pFastBac HTb vector (Invitrogen) containing an
N-terminal His6 tag with a recombinant Tobacco Etch Virus (TEV) protease
cleavage site. The recombinant bacmid DNAs were transfected into Sf9 cells
(Expression System). After two rounds of amplification, the baculovirus stock
was transfected into High Five cells (Invitrogen). The cells were harvested after
72 hr. To generate the selenomethionine (SeMet)-incorporated protein, High
Five cells cultured in ESF 921 media (Expression Systems) were centrifuged
at 1,0003 g and resuspended in ESF methionine-free media (Expression Sys-
tems) to prepare cultures with density 1 3 106 cells/ml. After 24 hr, the virus
stock was added at an multiplicity of infection of about 5 to infect the culture at
a cell density of 23 106 cells/ml in 1 l Fernbach flasks. SeMet was added 24 hr
postinfection to a concentration of 75 mg/l using a 10 mg/ml stock solution of
L-SeMet (Argos Organics) prepared in PBS. The cells were harvested at 54 hr
postinfection and pelleted at 3,000 3 g. The pellets from each liter of culture
were resuspended in 50 ml of a lysis buffer consisting of 50 mM Tris-HCl
(pH7.9), 250 mMNaCl, 10% glycerol, 5 mM imidazole, 5 mM b-mercaptoetha-
nol, and 0.1% Tween 20.
The cell suspensions were lysed by microfluidizer and then centrifuged at
16,000 rpm for 60 min. The supernatant was bound to a column of 10 ml
HisSelect (Sigma). Following a wash of the column with 30 column volumes
(CVs) of buffer consisting of 50 mM Tris-HCl (pH7.9), 250 mM NaCl, 10%
glycerol, 5 mM imidazole, 5 mM b-mercaptoethanol, and 0.1% Tween 20,
the protein was eluted with 30 CVs of 0%–50% gradient of 250 mM imidazole
buffer. The Ni-eluted SphK1 fractions were incubated with the TEV protease at
4C overnight to cleave the N-terminal His6-tag. The mixture was then loaded
onto a Ni-NTA column to remove the His6-tag and the TEV protease, which
was also His6 tagged. The protein was then further purified using an anion-
exchange column of Mono-Q (GE) and eluted with a linear salt gradient of
20–1000 mM NaCl in 50 mM Tris-HCl (pH8.5), 10% glycerol, 0.1% Tween
20, and 2 mM dithiothreitol (DTT). Further purification was performed using a
cation-exchange column of Mono-S (GE) and eluted with a linear gradient of
20–300 mM NaCl in 50 mM HEPES (pH 6.8), 10% glycerol, 0.1% Tween 20,
and 2 mM DTT. Finally, a gel filtration column of Superdex 200 (GE) was
used. The purified protein, which was pure, as demonstrated by a single
band on SDS gel, and catalytically active, was then concentrated to 1 mg/ml
in gel-filtration buffer of 50 mM Tris-HCl (pH8.5), 300 mM NaCl, 0.5 M GuHCl,
10% glycerol, 0.1% Tween 20, and 10 mM DTT.
Crystallization
The purified protein was concentrated to 10 mg/ml. For cocrystallization, pro-
tein at 1 mg/ml was incubated with 3-fold excess of inhibitors and/or 10-fold
excess of ATP/ADP for 2–3 hr before concentrating to 10 mg/ml. Crystalsreserved
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Molecular Basis of Sphingosine Kinase 1 Regulationwere grown at 16C by sitting drop from 1 ml of the protein solution plus 1 ml of
well solution containing 1.0–1.4 M ammonium sulfate (Hampton Research) in
0.3–1.3 M NaCl and 0.1 M Bis-Tris (pH 6.0). The crystals were transferred
stepwise into a well solution that contained additional ethylene glycol with a
final concentration of 30% (w/v) and then flash frozen in liquid nitrogen. The
selenomethionine-incorporated protein crystals were grown under similar
conditions and were frozen using similar procedures.
Data Collection, Structure Determination, and Refinement
Amultiwavelength anomalous data set for the selenomethionine-incorporated
protein crystal in the C2221 space group was collected on beamline 5.0.2 at
the Advance Light Source (ALS) in Berkeley, CA. The data were integrated
and scaled using the HKL2000 program (Otwinowski, 1997). Of 45 possible
selenomethionine sites, 30 were located using the program SHELXD
(Schneider and Sheldrick, 2002). The phases were further improved using
the program DM in the CCP4 suite (Collaborative Computational Project,
Number 4, 1994). The initial model was constructed using a combination of
manual tracing and ARP/wARP auto tracing (Perrakis et al., 1999). The model
was refined using the program REFMAC5 (Murshudov et al., 1997) and then
manually built by iterative rounds using the program COOT (Emsley and
Cowtan, 2004). Native data sets for apo and ligand cocrystals were also
collected on beamline 5.0.2 and were processed and integrated with the
programsMOSFLM and SCALA, respectively. Structures of the P212121 space
group were solved by the molecular replacement method using the program
Phaser (McCoy et al., 2007). The ligand geometry files were generated using
the program PRODRG (Schu¨ttelkopf and van Aalten, 2004). All figures were
prepared using the program PyMol (Schrodinger).
Enzymatic Assay
The SphK1 proteins, including wt, D81N, and D81A mutants, used for kinetic
study were E. coli-expressed full-length proteins of residues 2–384. SphK1
kinase activity was quantified using the DiscoveRx ADP Quest Assay kit
(DiscoverRx, Fremont, CA) to measure the accumulation of ADP that resulted
from the kinase reaction. To determine Km and Kcat values, purified wt or
mutant SphK1 (D81A and D81N) diluted in the assay buffer was added last to
start the reaction. The final reaction mix contained 15 mM HEPES (pH7.4),
20 mM NaCl, 1 mM EGTA, 0.02% Tween 20, 10 mM MgCl2, 0.1% bovine
g-globulins, 100 mM sphingosine, 10 nM wt or 100 nM D81N or D81A mutant
SphK1 enzymes, and various concentrations of ATP with a total volume of
50ml. Accumulation of ADP fromSphK1 kinase activitywasmeasured as a fluo-
rescence intensity signal with microplate reader Tecan Infinite M1000 (Tecan
Group Ltd.) at excitation/emission wavelengths of 530/590 nm. For more
details, see the description in the Supplemental Experimental Procedures.
To generate an ADP standard curve, various concentrations (10, 7.5, 5, 2.5,
1, 0.5, 0.25, and 0 mM) of ADPwere added into ADPQuest detectionmixture, in
the presence of SphK1 buffer but without SphK1 and sphingosine. The
standard curve was generated by fitting the ADP concentrations and the
corresponding signals (RFU) by linear regression.
The SphK1 reaction signals were converted into ADP concentrations with
the standard curve. The rate of the kinase reaction is generated by subtracting
the rate without sphingosine from the rate generated in the presence of 100 mM
sphingosine (mostly background, as the rate did not change much with
increasing concentration of ATP), indicating that there is very little ATPase
activity, if any. The Km and Kcat values were obtained by plotting the kinase
rates versus ATP concentrations with the Michaelis-Menten equation using
Prism 5 (GraphPad).
ACCESSION NUMBERS
The atomic coordinates and structure factor files have been deposited in the
Protein Data Bank under accession codes 3VZB (apo/lipid substrate), 3VZC
(with inhibitor), and 3VZD (with inhibitor and MgADP).
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